Solid tumour treatment developer Atreca has set a $100m target for an initial public offering that will provide GlaxoSmithKline with an exit.
Atreca, a US-based immunotherapy developer that counts pharmaceutical firm GlaxoSmithKline (GSK) as an investor, has filed for a $100m initial public offering on the Nasdaq Global Market.
Founded in 2010, Atreca is working on immunotherapeutics intended to fight off solid tumours by using antibody-target pairs indicated by the immune systems of patients who respond successfully to tumours.
The proceeds from the offering will support the progress of Atreca’s lead drug candidate, a monoclonal antibody called ATRC-101 through the dose-escalation…
